Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Qsymia Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects

NCT02229214
View directory record Official record
Conditions
Obesity
Interventions
Qsymia, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 30, 2026, 9:58 AM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

NCT06299891
View directory record Official record
Conditions
Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo
Drug · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 28 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults

NCT00600067
View directory record Official record
Conditions
Diabetes
Interventions
Phentermine/Topiramate, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.

NCT00842400
View directory record Official record
Conditions
Obesity
Interventions
Metformin, VI-0521, Sitagliptan, Probenecid
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 21, 2010 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)

NCT02659475
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
PHEN/TPM ER (Qsymia®)
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 30, 2026, 9:58 AM EDT
Recruiting Phase 4 Interventional

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

NCT07213466
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
Interventions
Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination)
Behavioral · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

Individualized Obesity Pharmacotherapy

NCT03374956
View directory record Official record
Conditions
Obesity
Interventions
Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Results available

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

NCT05579249
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

SMART Use of Medication for the Treatment of Adolescent Severe Obesity

NCT04007393
View directory record Official record
Conditions
Adolescent Obesity
Interventions
Lifestyle Modification Therapy (LSMT), Phentermine Pill, Topiramate Pill, Placebo
Behavioral · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

NCT02635386
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obesity
Interventions
Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA, Dapagliflozin plus Glucophage (MET ER), Phentermine /Topiramate (PHEN/ TPM) ER
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Results available

A Toolbox Approach to Obesity Treatment in Primary Care

NCT01922934
View directory record Official record
Conditions
Obesity
Interventions
Commercial weight loss program, Colorado Weigh, Meal replacements, Obesity pharmacotherapy, Recreation center passes
Behavioral · Dietary Supplement · Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 80 Years
Enrollment
4,730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 30, 2026, 9:58 AM EDT
Not yet recruiting Phase 2 Interventional

Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma

NCT07790913
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission, Non-Hodgkin Lymphoma in Remission, Cancer Survivorship
Interventions
Phentermine/Topiramate ER, Health Behavior and Lifestyle Counseling
Drug · Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 24 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Terminated Phase 4 Interventional Results available

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

NCT04531176
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds

NCT04095104
View directory record Official record
Conditions
Obesity, Morbid, Bariatric Surgery, Adolescent, Young Adult, Drug Therapy
Interventions
Phentermine, Immediate Release Topiramate, Placebo for Phentermine, Placebo for Immediate Release Topiramate
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 24 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 1 Interventional

FDA Approved Medication to Reduce Binge Eating and/or Purging

NCT02553824
View directory record Official record
Conditions
Binge Eating Disorder, Bulimia Nervosa
Interventions
Phentermine/Topiramate-First, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

NCT01950520
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qsymia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 35 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Phentermine/Topiramate for Uric Acid Stones

NCT04621929
View directory record Official record
Conditions
Obesity, Uric Acid Stones, Type 2 Diabetes Mellitus in Obese, Pre-Diabetes
Interventions
Phentermine / Topiramate Oral Product, Citrate Salts, Allopurinol, Diet
Drug · Combination Product
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Results available

Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy

NCT01087736
View directory record Official record
Conditions
PTSD, Alcohol Abuse, Alcoholism
Interventions
Topiramate, Placebo administration
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity

NCT04298203
View directory record Official record
Conditions
Obesity
Interventions
Phentermine-Topiramate, Meal Replacement Therapy, Placebo
Drug · Dietary Supplement · Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults

NCT00745251
View directory record Official record
Conditions
Sleep Apnea
Interventions
VI-0521, placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
30 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 30, 2026, 9:58 AM EDT
Active, not recruiting No phase listed Observational

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

NCT07188545
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome
Interventions
Intervention, Active Comparator
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
23,280,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Results available

A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents

NCT02714062
View directory record Official record
Conditions
Pediatric Obesity, Childhood Obesity
Interventions
Placebo, VI-0521 Mid Dose, VI-0521 Top Dose
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Marrero, Louisiana • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 30, 2026, 9:58 AM EDT
Active, not recruiting No phase listed Observational

Weight Loss Management in Endometrial Cancer Survivors

NCT06877572
View directory record Official record
Conditions
Endometrial Cancer Survivors, Weight Management, Early Stage Endometrial Cancer
Interventions
Weight loss with pharmacotherapy, Weight loss without pharmacotherapy
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Active, not recruiting No phase listed Observational

Anti-obesity Pharmacotherapy and Inflammation

NCT05756764
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
35 Years to 60 Years
Enrollment
30 participants
Timeline
2023 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 30, 2026, 9:58 AM EDT